bictegravir

This page shows the latest bictegravir news and features for those working in and with pharma, biotech and healthcare.

GSK considers more divestments to help R&D push

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.

ViiV builds case for switching to its two-drug HIV combinations

ViiV needs to convince patients, prescribers and payers that there is a real benefit to that approach if it is to challenge drugs like Gilead’s three-drug Biktarvy
ViiV bags EU okay for new two-drug HIV therapy

bictegravir/emtricitabine/tenofovir alafenamide) product.
Shingrix lifts GSK in Q1, but two more vaccines are culled

such as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has started to chip away at growth levels.
Dovato approval key for Glaxo in HIV treatment

This gives the company the upperhand over its chief rival, Gilead, which has come to dominate this segment since it launched Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [TAF]) in February 2018.
GSK’s says depot HIV injection works over three years

drug tablet Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

More from news
Approximately 2 fully matching, plus 19 partially matching documents found.

Add my company

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...